CN117695284B - 冠状病毒感染的治疗 - Google Patents
冠状病毒感染的治疗 Download PDFInfo
- Publication number
- CN117695284B CN117695284B CN202311591091.6A CN202311591091A CN117695284B CN 117695284 B CN117695284 B CN 117695284B CN 202311591091 A CN202311591091 A CN 202311591091A CN 117695284 B CN117695284 B CN 117695284B
- Authority
- CN
- China
- Prior art keywords
- sars
- cov
- treatment
- patients
- study
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/485—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M31/00—Devices for introducing or retaining media, e.g. remedies, in cavities of the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Engineering & Computer Science (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (12)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062987429P | 2020-03-10 | 2020-03-10 | |
| US62/987,429 | 2020-03-10 | ||
| US202063003601P | 2020-04-01 | 2020-04-01 | |
| US63/003,601 | 2020-04-01 | ||
| US202063034817P | 2020-06-04 | 2020-06-04 | |
| US63/034,817 | 2020-06-04 | ||
| US202063074799P | 2020-09-04 | 2020-09-04 | |
| US63/074,799 | 2020-09-04 | ||
| US202063125427P | 2020-12-15 | 2020-12-15 | |
| US63/125,427 | 2020-12-15 | ||
| PCT/IB2021/000131 WO2021181157A1 (en) | 2020-03-10 | 2021-03-08 | Treatment of coronavirus infection |
| CN202180022144.5A CN115515560B (zh) | 2020-03-10 | 2021-03-08 | 冠状病毒感染的治疗 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202180022144.5A Division CN115515560B (zh) | 2020-03-10 | 2021-03-08 | 冠状病毒感染的治疗 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN117695284A CN117695284A (zh) | 2024-03-15 |
| CN117695284B true CN117695284B (zh) | 2025-06-17 |
Family
ID=76548186
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202311591091.6A Active CN117695284B (zh) | 2020-03-10 | 2021-03-08 | 冠状病毒感染的治疗 |
| CN202180022144.5A Active CN115515560B (zh) | 2020-03-10 | 2021-03-08 | 冠状病毒感染的治疗 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202180022144.5A Active CN115515560B (zh) | 2020-03-10 | 2021-03-08 | 冠状病毒感染的治疗 |
Country Status (11)
| Country | Link |
|---|---|
| US (6) | US11052073B1 (https=) |
| EP (1) | EP4117630A4 (https=) |
| JP (1) | JP7822946B2 (https=) |
| KR (1) | KR20220151613A (https=) |
| CN (2) | CN117695284B (https=) |
| AU (1) | AU2021235304A1 (https=) |
| BR (1) | BR112022017923A2 (https=) |
| CA (1) | CA3174438A1 (https=) |
| IL (1) | IL295658A (https=) |
| MX (1) | MX2022011173A (https=) |
| WO (1) | WO2021181157A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20210244705A1 (en) * | 2020-02-07 | 2021-08-12 | Centre For Digestive Diseases | Therapeutic compositions, products of manufacture and methods for ameliorating or preventing coronavirus infection |
| CN117695284B (zh) | 2020-03-10 | 2025-06-17 | 红山生物医药有限公司 | 冠状病毒感染的治疗 |
| US11471448B2 (en) * | 2020-12-15 | 2022-10-18 | Redhill Biopharma Ltd. | Sphingosine kinase 2 inhibitor for treating coronavirus infection in moderately severe patients with pneumonia |
| CN113398219A (zh) * | 2021-06-30 | 2021-09-17 | 广州白云山星群(药业)股份有限公司 | 橘红痰咳浸膏在制备抑制人冠状病毒感染的药物中的用途 |
| EP4286851A1 (en) | 2022-06-01 | 2023-12-06 | Universität Wien | Methods and means for molecular characterization of post-viral fatigue syndrome |
| WO2025133697A2 (en) * | 2023-12-20 | 2025-06-26 | Redhill Biopharma Ltd. | Combination therapy for inhibition of ebolavirus |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108135168A (zh) * | 2015-05-21 | 2018-06-08 | 凯莫森特里克斯股份有限公司 | Ccr2调节剂 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7342018B2 (en) | 1998-07-20 | 2008-03-11 | Wilex Ag | Urokinase inhibitors and uses thereof |
| US6624169B1 (en) | 1998-07-20 | 2003-09-23 | Wilex Biotechnology Gmbh | Urokinase inhibitors |
| AU9059798A (en) | 1998-09-18 | 2000-04-10 | Pentapharm Ag | Urokinase inhibitors |
| DE50211672D1 (de) | 2001-03-21 | 2008-03-27 | Wilex Ag | Urokinase-inhibitoren |
| CH695999A5 (de) | 2002-02-28 | 2006-11-15 | Wilex Ag | Verfahren zur Herstellung von 3- Amidinophenylalanin-Derivaten. |
| WO2004011449A2 (de) | 2002-07-25 | 2004-02-05 | Wilex Ag | Verfahren zur herstellung von phenylalanin-derivaten |
| DE10238048A1 (de) | 2002-07-25 | 2004-02-05 | Wilex Ag | Verfahren zur Herstellung von Phenylalanin-Derivaten |
| US9770349B2 (en) * | 2002-11-13 | 2017-09-26 | University Of Virginia Patent Foundation | Nanoporous stents with enhanced cellular adhesion and reduced neointimal formation |
| DE10323898A1 (de) | 2003-05-26 | 2004-12-23 | Wilex Ag | Hydroxyamidin- und Hydroxyguanidin-Verbindungen als Urokinase-Hemmstoffe |
| RU2234313C1 (ru) | 2003-06-04 | 2004-08-20 | Кривошеин Юрий Семенович | Средство инактивации коронавирусов |
| GB0420874D0 (en) | 2004-09-20 | 2004-10-20 | Swetree Technologies Ab | Modulation of flowering time and growth cessation in perennial plants |
| DE102004045720A1 (de) | 2004-09-21 | 2006-03-23 | Wilex Ag | Stabile Dosierungsform von Phenylalanin-Derivaten |
| BRPI0516106B1 (pt) | 2004-10-14 | 2021-08-24 | Wilex Ag | Métodos para purificação e preparação de derivados de 3-hidroxiamidinofenilalanina, e para produção de derivados de 3-amidinofenilalanina |
| DE102004057195A1 (de) | 2004-11-26 | 2006-06-01 | Wilex Ag | Kristalline Modifikationen von N-Alpha-(2,4,6-Triisopropylphenylsulfonyl)-3-hydroxyamidino-(L)-phenylalanin-4-ethoxycarbonylpiperazid und/oder Salzen davon |
| US8324237B2 (en) | 2005-05-20 | 2012-12-04 | Smith Charles D | Methods for the treatment and prevention of inflammatory diseases |
| ES2528451T3 (es) | 2005-06-17 | 2015-02-10 | Apogee Biothechnology Corporation | Inhibidores de esfingosina cinasa |
| WO2012166859A2 (en) * | 2011-06-01 | 2012-12-06 | The Curators Of The University Of Missouri | Modulation of sphingosine 1-phosphate metabolizing enzymes for the treatment of negative-strand rna virus infections |
| WO2015161908A1 (en) * | 2014-03-11 | 2015-10-29 | Ludwig-Maximilians-Universität München | Non-immunosuppressive cyclophilin inhibitors for the treatment of coronavirus infections |
| CA2965258C (en) * | 2014-10-24 | 2023-09-19 | Redhill Biopharma Ltd. | Therapy for inhibition of single-stranded rna virus replication |
| WO2017060771A2 (en) * | 2015-10-06 | 2017-04-13 | Redhill Biopharma Ltd. | Combination therapies for treating cancer |
| US10195188B2 (en) * | 2016-06-13 | 2019-02-05 | Chemocentryx, Inc. | Method of treating pancreatic cancer |
| US10251888B2 (en) * | 2016-06-13 | 2019-04-09 | Chemocentryx, Inc. | Method of treating pancreatic cancer |
| DE102018217334A1 (de) * | 2018-10-10 | 2020-04-16 | Harbins Ruhr Bioscience, Inc. | Sphingoid-Base und/oder Wirkstoff zur Verwendung bei der Prophylaxe und/oder Therapie einer viralen Infektion und/oder viralen Infektionskrankheit oder der Desinfektion, Nahrungsmittel/Nahrungsergänzungsmittel, Futtermittel/Futterergänzungsmittel und Pflanzenschutzmittel |
| CN117695284B (zh) * | 2020-03-10 | 2025-06-17 | 红山生物医药有限公司 | 冠状病毒感染的治疗 |
| EP4126234A1 (en) | 2020-04-02 | 2023-02-08 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Compositions for coronavirus infection treatment and/or prevention |
-
2021
- 2021-03-08 CN CN202311591091.6A patent/CN117695284B/zh active Active
- 2021-03-08 JP JP2022554382A patent/JP7822946B2/ja active Active
- 2021-03-08 US US17/195,279 patent/US11052073B1/en active Active
- 2021-03-08 KR KR1020227029182A patent/KR20220151613A/ko active Pending
- 2021-03-08 BR BR112022017923A patent/BR112022017923A2/pt unknown
- 2021-03-08 EP EP21768527.0A patent/EP4117630A4/en active Pending
- 2021-03-08 CA CA3174438A patent/CA3174438A1/en active Pending
- 2021-03-08 CN CN202180022144.5A patent/CN115515560B/zh active Active
- 2021-03-08 AU AU2021235304A patent/AU2021235304A1/en active Pending
- 2021-03-08 WO PCT/IB2021/000131 patent/WO2021181157A1/en not_active Ceased
- 2021-03-08 MX MX2022011173A patent/MX2022011173A/es unknown
- 2021-03-08 US US17/195,333 patent/US11045453B1/en active Active
- 2021-03-08 IL IL295658A patent/IL295658A/en unknown
- 2021-06-10 US US17/344,430 patent/US11918560B2/en active Active
- 2021-06-30 US US17/364,386 patent/US12551469B2/en active Active
- 2021-10-15 US US17/502,932 patent/US11364227B2/en active Active
-
2024
- 2024-01-30 US US18/426,914 patent/US12502381B2/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108135168A (zh) * | 2015-05-21 | 2018-06-08 | 凯莫森特里克斯股份有限公司 | Ccr2调节剂 |
Also Published As
| Publication number | Publication date |
|---|---|
| US11918560B2 (en) | 2024-03-05 |
| CN117695284A (zh) | 2024-03-15 |
| IL295658A (en) | 2022-10-01 |
| US11052073B1 (en) | 2021-07-06 |
| US12551469B2 (en) | 2026-02-17 |
| CN115515560A (zh) | 2022-12-23 |
| US11045453B1 (en) | 2021-06-29 |
| KR20220151613A (ko) | 2022-11-15 |
| JP2023517920A (ja) | 2023-04-27 |
| CN115515560B (zh) | 2023-12-15 |
| MX2022011173A (es) | 2022-10-18 |
| CA3174438A1 (en) | 2021-09-16 |
| US20240350461A1 (en) | 2024-10-24 |
| US20210299108A1 (en) | 2021-09-30 |
| US12502381B2 (en) | 2025-12-23 |
| AU2021235304A1 (en) | 2022-10-06 |
| EP4117630A1 (en) | 2023-01-18 |
| US11364227B2 (en) | 2022-06-21 |
| BR112022017923A2 (pt) | 2022-10-18 |
| EP4117630A4 (en) | 2024-07-03 |
| JP7822946B2 (ja) | 2026-03-03 |
| WO2021181157A1 (en) | 2021-09-16 |
| US20220031682A1 (en) | 2022-02-03 |
| US20210322390A1 (en) | 2021-10-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN117695284B (zh) | 冠状病毒感染的治疗 | |
| US11324708B1 (en) | Niclosamide formulations for treating disease | |
| US20230190685A1 (en) | Formulation | |
| US20230218596A1 (en) | Methods involving neutrophil elastase inhibitor alvelestat for treating coronavirus infection | |
| CN116133657A (zh) | 治疗covid-19疾病的新组合物和方法 | |
| CN109789193A (zh) | 使用间α抑制蛋白治疗肺病的方法 | |
| CN115701984A (zh) | 治疗 | |
| WO2021217702A1 (zh) | 一种预防或治疗covid-19新冠肺炎的药物、食物及其应用 | |
| CN115666572A (zh) | 用于预防或治疗流行性rna病毒传染病的药物组合物 | |
| Nodarse-Cuní et al. | Interferon alpha-2b as adjuvant treatment of recurrent respiratory papillomatosis in Cuba: National Programme (1994–1999 report) | |
| JP7840570B2 (ja) | コロナウイルス感染症の処置のための方法 | |
| US11160814B1 (en) | Methods of treatment for disease from coronavirus exposure | |
| WO2023008530A1 (ja) | 新型コロナウイルス感染症治療剤 | |
| KR20230021009A (ko) | 항바이러스 치료로서의 아젤라스틴 | |
| RU2837859C1 (ru) | Лечение коронавирусной инфекции | |
| JP2023517771A (ja) | 抗新型コロナウイルス感染症の医薬品、食品、及び使用 | |
| WO2021200651A1 (ja) | コロナウイルス感染症治療剤 | |
| US12115150B2 (en) | Biomarkers of coronavirus pneumonia | |
| CN117618436A (zh) | 一种稠环嘧啶类化合物的用途 | |
| WO2025235945A1 (en) | Methods of treating viral infections using a fusion inhibitor | |
| US20220304959A1 (en) | Treatment of long haulers syndrome with niclosamide | |
| CN116472054A (zh) | 用于改善SARS-CoV-2感染患者的预后的吸入型干扰素-β |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |